Sanofi-Aventis Drug Launch Targets Mexican Obesity Crisis

December 2006 | Product Launch

Sanofi-Aventis has received a marketing authorisation for its potential blockbuster obesity treatment Acomplia (rimonabant) in Mexico, as the company continues to await approval from the US FDA. The approval gives the French multinational an opportunity to market one of its most hyped new medicines in the world's ninth-largest pharmaceutical market. But as Mexico struggles to get to grip with its current obesity epidemic, restricted state pharmaceutical coverage and limited out-of-pocket spending will likely fail to deliver the fastest-growing segment of the obesity market, Mexico's

If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.